Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus (NASDAQ: AGEN) announced promising results from a Phase 1b study on botensilimab, a CTLA-4 antibody, combined with balstilimab, a PD-1 antibody, targeting recurrent platinum-resistant ovarian cancer. Presenting at the SGO 2023 Annual Meeting, the study reported a remarkable 33% overall response rate with 67% disease control among 24 evaluable patients. This efficacy surpasses past PD-(L)1/CTLA-4 combinations that showed only 3-10% response rates. The patients involved were heavily pre-treated, suggesting the combination's transformative potential. Agenus is expanding its clinical trials further across various cancer types.
Agenus Inc. provided a corporate update and reported Q4 and full year 2022 financial results, highlighting its lead asset, botensilimab, which has shown promising overall response rates in various cancers. Key results include a 23% response rate in microsatellite stable colorectal cancer and 50% in PD-(L)1 refractory non-small cell lung cancer. A confirmatory Phase 3 trial for MSS CRC is planned for 2023. The company announced existing collaborations could yield $2.7B in milestones and royalties. However, Agenus reported a net loss of $74 million for Q4, totaling $231 million for the year, alongside a cash balance of $193 million.
Agenus has announced the cancellation of its conference call scheduled for March 13, 2023, regarding its minority cash holdings at Silicon Valley Bank (SVB). This decision follows the government's announcement concerning access to SVB deposits. Agenus is a clinical-stage immuno-oncology company focused on developing therapies that enhance the body's immune response against cancer and infections. The company's approach includes a wide array of antibody therapeutics and adoptive cell therapies. Headquartered in Lexington, MA, Agenus continues to aim for innovative cancer treatment solutions.
Agenus (Nasdaq: AGEN), a clinical-stage immuno-oncology company, has announced a conference call scheduled for March 13, 2023, at 8:30 a.m. ET. The purpose of the call is to discuss its minority cash holdings at Silicon Valley Bank (SVB). Interested participants can dial in using specific numbers provided in the release. Agenus focuses on developing therapies to enhance the immune system's ability to combat cancer and infections, leveraging its broad range of antibody therapeutics, cell therapies, and adjuvants. The company is headquartered in Lexington, Massachusetts.
Agenus (Nasdaq: AGEN) will release its fourth quarter and full year 2022 financial results on March 14, 2023, before the market opens. The company specializes in immuno-oncology, targeting cancer and infectious diseases. Following the results, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the financial outcomes and provide a corporate update. Investors can access the call via dial-in numbers or through a live webcast available on the company’s official website. This event is pivotal for stakeholders, as it will outline key financial metrics and future strategies in the competitive biotechnology landscape.
Agenus (Nasdaq: AGEN), a clinical-stage immuno-oncology company, will present updated data on its lead program botensilimab at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer from March 25-28, 2023, in Tampa, FL.
The presentation will focus on the combination of botensilimab with balstilimab in patients with recurrent platinum refractory/resistant ovarian cancer, scheduled for March 27 at 9:18am ET. Botensilimab aims to treat 'cold' tumors, showing promising results in over 300 patients across various cancers. A global Phase 3 trial in microsatellite-stable colorectal cancer is planned for 2023.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen, Chairman and CEO, along with Dr. Steven O’Day, Chief Medical Officer, will present at two upcoming investor conferences. The Guggenheim 5th Annual Oncology Day will feature a fireside chat on February 9, 2023, at 9:35 AM ET, while the SVB Securities Global Biopharma Conference will host a virtual fireside chat on February 16, 2023, at 10:00 AM ET. Interested parties can access live webcasts through the company’s website. Agenus focuses on cancer immunotherapy, leveraging various therapeutic approaches and resources.
Agenus reported promising clinical data from a Phase 1b study of botensilimab combined with balstilimab in treating microsatellite stable colorectal cancer (MSS CRC). In an expanded cohort of 70 heavily pre-treated patients, the overall response rate (ORR) was 23%, while the disease control rate (DCR) was 76%. Remarkably, 69% of responses were ongoing at the data cut-off, and median overall survival has not yet been reached. The company plans to initiate a Phase 3 trial for MSS CRC in 2023, underscoring a commitment to address the significant unmet needs in this patient population.
Agenus (NASDAQ: AGEN), an immuno-oncology firm, announced participation by Chairman and CEO Dr. Garo Armen and Chief Medical Officer Dr. Steven O’Day in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on January 18th at 11:30 am ET. This event offers insights into Agenus's innovative therapies targeting cancer and infections. Interested participants can register for the webcast at B Riley's website. An archived version will be available later on Agenus's Investor page, providing ongoing updates about the company's developments.
Agenus Inc. (NASDAQ: AGEN) announced it will present expanded data on botensilimab, an anti-CTLA-4, in combination with balstilimab, an anti-PD-1, at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) from January 19-21, 2023, in San Francisco, CA. The presentation will focus on data from the microsatellite stable colorectal cancer cohort of its Phase 1 study and occurs on January 21, 2023, at 10:00am ET. Abstract details, including the presenting author, will be released on January 17, 2023.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
